XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2018
Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Remainder of transaction price, variable consideration from estimated future co-development billing $ 2.1    
Japan [Member] | Astellas Agreement [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Changes in revenue due to prior period adjustment   $ 14.9  
Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Remainder of transaction price, variable consideration from estimated future co-development billing     $ 19.4
Europe [Member] | Astellas Agreement [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Changes in revenue due to prior period adjustment     (0.1)
U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Remainder of transaction price, variable consideration from estimated future co-development billing     223.7
U.S./RoW and China [Member] | AstraZeneca Agreements [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Changes in revenue due to prior period adjustment     $ (0.1)